GAMMA Investing LLC Has $2.43 Million Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

GAMMA Investing LLC grew its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 25.1% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,002 shares of the pharmaceutical company's stock after acquiring an additional 1,005 shares during the period. GAMMA Investing LLC's holdings in Vertex Pharmaceuticals were worth $2,425,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the stock. Farther Finance Advisors LLC increased its stake in shares of Vertex Pharmaceuticals by 19.2% during the 1st quarter. Farther Finance Advisors LLC now owns 2,871 shares of the pharmaceutical company's stock worth $1,392,000 after purchasing an additional 462 shares during the last quarter. Daymark Wealth Partners LLC acquired a new stake in shares of Vertex Pharmaceuticals in the first quarter worth about $226,000. Portside Wealth Group LLC boosted its stake in shares of Vertex Pharmaceuticals by 30.0% during the 1st quarter. Portside Wealth Group LLC now owns 2,945 shares of the pharmaceutical company's stock worth $1,428,000 after acquiring an additional 679 shares in the last quarter. Moss Adams Wealth Advisors LLC increased its holdings in shares of Vertex Pharmaceuticals by 62.5% during the 1st quarter. Moss Adams Wealth Advisors LLC now owns 863 shares of the pharmaceutical company's stock valued at $419,000 after acquiring an additional 332 shares during the last quarter. Finally, Capital Investment Advisors LLC raised its stake in shares of Vertex Pharmaceuticals by 22.6% in the 1st quarter. Capital Investment Advisors LLC now owns 1,032 shares of the pharmaceutical company's stock valued at $500,000 after acquiring an additional 190 shares in the last quarter. 90.96% of the stock is owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Price Performance

Shares of VRTX traded down $2.10 during trading hours on Friday, hitting $441.30. The stock had a trading volume of 3,615,473 shares, compared to its average volume of 1,418,238. Vertex Pharmaceuticals Incorporated has a 52 week low of $377.85 and a 52 week high of $519.88. The stock has a market capitalization of $113.33 billion, a price-to-earnings ratio of -112.58 and a beta of 0.41. The company's fifty day moving average is $454.50 and its two-hundred day moving average is $458.76. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.65 and a quick ratio of 2.29.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share for the quarter, missing the consensus estimate of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative return on equity of 3.36% and a negative net margin of 8.91%. The firm had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.85 billion. During the same period in the previous year, the business posted $4.76 EPS. The business's quarterly revenue was up 2.6% on a year-over-year basis. On average, analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have issued reports on VRTX. Royal Bank Of Canada set a $420.00 target price on Vertex Pharmaceuticals and gave the stock a "sector perform" rating in a research report on Tuesday, June 17th. HC Wainwright reissued a "buy" rating and set a $550.00 price objective on shares of Vertex Pharmaceuticals in a research report on Monday, June 23rd. Morgan Stanley cut their target price on shares of Vertex Pharmaceuticals from $464.00 to $460.00 and set an "equal weight" rating for the company in a research note on Friday, June 20th. Wolfe Research lowered shares of Vertex Pharmaceuticals from an "outperform" rating to a "peer perform" rating in a research report on Wednesday, May 7th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Vertex Pharmaceuticals from $512.00 to $515.00 and gave the company an "overweight" rating in a research report on Tuesday, May 6th. Fourteen investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Vertex Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $511.62.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.